News articles about Xenon Pharmaceuticals (NASDAQ:XENE) have trended somewhat positive on Wednesday, according to Accern. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Xenon Pharmaceuticals earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.4968083838898 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Separately, Zacks Investment Research upgraded Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 21st.

Shares of Xenon Pharmaceuticals (XENE) traded down $0.05 during trading hours on Wednesday, reaching $2.45. 12,100 shares of the company were exchanged, compared to its average volume of 90,301. Xenon Pharmaceuticals has a 1 year low of $2.10 and a 1 year high of $9.95.

In related news, Director Mohammad Azab acquired 15,000 shares of the stock in a transaction dated Wednesday, November 15th. The stock was bought at an average cost of $2.22 per share, with a total value of $33,300.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 9.40% of the company’s stock.

WARNING: This piece was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/20/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-xenon-pharmaceuticals-xene-stock-price.html.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).

Insider Buying and Selling by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.